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Abstract 
Manual development of liquid chromatography tandem-mass spectrometry (LC-MS/MS) 
methods is a rate limiting step in analytical laboratories, particularly if several compounds have 
the same multiple reaction monitoring (MRM) transitions. This study describes the application of 
Multi-platform Unbiased optimisation of Spectrometry via Closed-Loop Experimentation 
(MUSCLE) software to automate the development of an LC-MS/MS method to measure multiple 
metabolites of vitamin D. Comparison with a manually developed method for the same 
compounds was used to evaluate the effectiveness of MUSCLE in improving method 
parameters. LC and MS parameter ranges were set up in MUSCLE, which optimised the method 
during a fully-automated 200 sample sequence. Visual scripts altered method parameters after 
each sample run while a closed-loop multi-objective optimisation approach identified optimum 
instrument parameters throughout the sequence to improve sensitivity and run time. The 
optimised sample run developed using MUSCLE shortened analysis time for 10 metabolites 
from 8.2 minutes to 6.2 minutes. This was achieved by increased initial methanol concentration 
in the mobile phase and an altered gradient that increased the in-run organic mobile phase. 
However, MS parameters could not be optimised further to improve analyte sensitivity over 
manual optimisation, although in most cases MUSCLE confirmed the manually optimised 
conditions. Comparison between each of the developed methods showed no significant analyte 
bias between methods. MUSCLE has been shown here to automate and improve the throughput 
of a multiple analyte vitamin D LC-MS/MS method. Utilisation of this software could be applied 
to industries requiring fast automated method development such as clinical and pharmaceutical 
laboratories. 
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1 Introduction 
Liquid chromatography tandem-mass spectrometry (LC-MS/MS) has become the primary 
method of choice for quantitation of compounds such as endocrine and pharmaceutical owing to 
fast sample analysis and improved accuracy over other techniques.
1
 Increased demand has been 
placed on developing high throughput multi-analyte LC-MS/MS methods, particularly in clinical 
laboratories requiring rapid results.
1
 The development of LC-MS/MS methods can often be 
challenging as both LC and MS parameters need to be optimised to produce accurate and 
sensitive methods to achieve the necessary user outputs. To determine optimum multiple reaction 
monitoring (MRM) transitions it is usually necessary manually tune each sample within the 
method into the mass spectrometer. Optimisation of LC parameters are also required to achieve 
high resolution and hence separation of the analytes, particularly those with equal mass-to-
charge ratios (m/z) and MRM transitions.
2, 3
 The development of LC-MS/MS methods can 
therefore be time consuming and labour intensive to gain optimal method conditions. 
 
MUSCLE (Multi-objective Unbiased optimisation of Spectrometry via Closed Loop 
Experimentation) is a software platform that has been developed to aid LC-MS/MS method 
development. The software fully automates the development of LC-MS/MS methods for targeted 
analytes, gaining optimum runtime, resolution and sensitivity during the course of a sample 
sequence.
4
 MUSCLE applies visual scripting to enable the software to operate the LC-MS/MS 
system independently, whilst a closed loop optimisation approach using a genetic algorithm is 
used to optimise the method throughout each sample run.
4
 The current study describes the 
application of MUSCLE software for the automated development of an LC-MS/MS method to 
measure multiple vitamin D metabolites. A comparison between optimised method conditions 
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obtained by MUSCLE with a method that was previously developed manually,
5
 was used to 
assess the effectiveness of MUSCLE in optimising LC and MS conditions. Previous reports have 
described automated method development using a closed-loop strategy to optimise method 
parameters for non-targeted analysis of metabolites on gas chromatography mass spectrometry 
(GC-MS) and LC-MS/MS platforms.
4, 6-8
 The development of a six steroid LC-MS/MS method 
was also developed using MUSCLE, which improved the run time and sensitivity of steroid 
analytes.
4
 However, to our knowledge, this is the first automated approach for LC-MS/MS 
method development that has been applied to vitamin D metabolites that include analytes with 
equal m/z. 
  
The metabolic pathway of vitamin D is complex, providing several challenges in developing an 
LC-MS/MS method to target multiple vitamin D metabolites. There are two forms of vitamin D, 
D3 and D2, which are respectively produced by the action of ultraviolet light on skin, or obtained 
from plants.
9
 The metabolite 1α,25-dihydroxyvitamin D (1α,25(OH)2D3), present at low 
picomolar endogenous concentrations, is the biologically active form which binds to intracellular 
vitamin D receptor.
10
 However, the precursor to 1α,25(OH)2D3, 25-hydroxvitamin D (25(OH)D) 
is the principal determinant of vitamin D-sufficiency/deficiency, and is the most commonly 
quantified metabolite of vitamin D. Several metabolites that form other parts of the vitamin D 
metabolic pathway are normally found at low endogenous concentrations, which is challenging 
when developing methods for accurately measuring these compounds. Stereoisomers and chiral 
metabolites of vitamin D require baseline separation by LC in order to be quantified by mass 
spectrometry. This includes separating D3 and D2 C3-epimers, 3-epi-25OHD from 25(OH)D, 
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formed from epimerisation.
11
 Chiral metabolites 23R,25(OH)2D3 and 24R,25(OH)2D3 which are 
thought to be non-active, have the same m/z as 1α,25(OH)2D3, also require separation.
10
  
 
Previously we have reported a manual method for quantification of 10 metabolites of vitamin D, 
including separation of compounds with equal m/z.
5
 Routine analysis of serum samples 
demonstrated quantitation of several metabolites along the vitamin D metabolic pathway 
including 25OHD3, 3-epi-25OHD3, 24R,25(OH)2D3, 1α,25(OH)2D3 and 25OHD2. The 
application of MUSCLE for developing this method significantly reduced the optimisation time 
for method development, as well as improving assay throughput and sensitivity. As this software 
can work independently,
4
 it is anticipated that a further benefit will be reduced labour 
requirements needed for the development of this method. 
 
2 Experimental 
2.1 Reagents and chemicals 
Vitamin D reference standards (Table 3) and formic acid were purchased from Sigma Aldrich 
(Pool, UK). 7αC4 reference standard was purchased from LGC standards (Teddington, UK). A 
Lux cellulose-3 chiral column (100 mm, 2 mm, 3µm) was purchased from Phenomenex 
(Macclesfield, UK) and a 2µm inline filter was purchased from Waters Corporation (Manchester, 
UK). LC-MS grade water was purchased from Fisher Scientific (Leicestershire, UK) and LC-MS 
grade methanol was purchased from Greyhound Chromatography (Merseyside, UK). Vitamin D 
depleted serum was purchased from Golden West Biologicals Inc. (Temecula, US). 
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2.2 Manually developed LC-MS/MS method for measuring multiple vitamin D metabolites 
The optimisation steps and method parameters for a manually developed LC-MS/MS method to 
quantify 10 vitamin D metabolites has been described previously.
5
 Each metabolite was 
manually tuned into the mass spectrometer in methanol at 1 µg/mL to determine optimum MRM 
transitions. A Lux cellulose-3 chiral column achieved separation of analytes with equal MRM 
transitions with an overall run time of 8.2 minutes. Validation of this method was performed in 
accordance to US Food and Drug Administration (FDA) guidelines using a Waters ACQUITY 
UPLC coupled to a Waters Xevo-MS and TQ-S mass spectrometer. 
 
2.3 MUSCLE software 
A detailed description of the MUSCLE software and applications has been described 
previously.
4
 The software works on a stand-alone desktop application. For the MUSCLE 
sequence a sample has been defined as an individual run in the sequence were a 1 µL injection is 
taken from the same standard solution. The software package MUSCLE uses closed-loop 
optimisation to automate LC-MS/MS method development. A multi-objective genetic algorithm 
(GA) simultaneously optimises a set of user defined LC and MS parameters. The software 
utilises user-defined visual scripts to change the values of each of the instrument parameters (LC 
& MS) that are being optimised, with the values being entered for the parameters being decided 
by the GA. The GA chooses values for each run based upon the previous runs in the sequence 
that have produced favourable results. Each LC-MS/MS run is evaluated based upon three 
objectives; minimisation of run time (measured by the retention time of the last eluting peak), 
maximisation of total number of detected peaks and maximisation of total peak area. MUSCLE 
maintains a set of preferred samples, each with a specific set of LC and MS parameters, which is 
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updated every generation of the GA. The maintained set of samples will be updated every 
generation if an improvement is made based upon the objectives. As MUSCLE optimises for 
multiple objectives simultaneously, the set of preferred samples can contain many runs which 
represent a trade-off between the objectives of the GA, e.g. one run may have a very short run 
time but not detect all of the peaks, whereas another run may have good sensitivity, detect all the 
peaks, but have a much longer run time. It is up to the user to select from this set the run which 
suits best. 
 
2.4 Experiment and sequence set up 
The optimisation of this vitamin D method using MUSCLE was performed on a Waters Xevo 
mass spectrometer coupled to a Waters AQUITY UPLC. An electrospray ionisation source was 
used in positive ionisation mode. A Phenomenex Lux cellulose-3 chiral column (100 mm, 2 mm, 
3 µm) was used, heated at 60 
o
C with a flow rate of 0.330 mL/min. The mobile phase solution 
was water/methanol/0.1% formic acid, which had been previously shown to be the optimal 
phases when the method was developed manually.
5
 
 
User defined LC and MS conditions were set up within software, setting minimum and 
maximum value ranges to be used by the genetic algorithm when altering method conditions. 
The user defined LC and MS conditions for this application are displayed in (Table 1). The total 
number of samples in the sequence was 200 with a 1 µL injection of the same standard solution 
for each sample run. The first 20 samples were set to have random LC and MS values 
determined by the software, within the minimum and maximum ranges set. The remaining 
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samples in the sequence applied the genetic algorithm for optimising method parameters. The 
genetic algorithm crossover rate was set at 0.7 and the mutation rate was 0.2. 
 
2.5 Sample preparation and method validation 
Sample collection and analysis was approved by the Scientific Committee of the NIHR-
Wellcome Trust Clinical Research Facility at Queen Elizabeth Hospital Birmingham. Ethical 
approval was obtained from the NRES Committee West Midlands (REC reference no. for 
CHHIP 14/WM/1146). Written informed consent was obtained for sample collection. 
 
Sample preparation and analysis of samples was performed as previously described.
5
 Briefly, 
supported liquid-liquid extraction was performed following protein precipitation prior to LC-
MS/MS analysis. Internal standards 25OHD3-d3, 3-epi-25OHD3-d3 and 1α,25(OH)2D3 were 
added to samples and used for quantitation. 
 
Method validation was carried out with the optimised methods obtained by MUSCLE, compared 
with the manually developed method for accuracy, precision, assessing matrix effects. Validation 
was performed based on US FDA guidelines.
12
 The analysis of 10 routine serum samples was 
performed on each of the three methods to compare the quantified concentration of each analyte 
to inform of the standardisation of measurements. Serum samples were collected as previously 
described.
5
 
 
2.6 Data analysis 
Data analysis was performed using MUSCLE in tandem with Waters MassLynx software. The 
MUSCLE software was used to identify sample run times, peak areas and numbers of separated 
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peaks of each sample. Waters MassLynx software was used to confirm chromatographic 
conditions. SPSS statistics software V22 was used for comparing methods using regression 
analysis, Bland-Altman plots and independent T-tests. SigmaPlot V13 was used to assess mass 
spectrometry conditions on peak area. 
3 Results and discussion 
3.1 Optimisation of MUSCLE method 
MUSCLE was used to optimise the development of a vitamin D LC-MS/MS method, 
determining whether the optimum LC and MS conditions can be enhanced with the use of this 
automated software. The assay sequence took approximately 30 hours to complete the 200 
sample runs. The selected run revealed an improved set of LC conditions that shortened the 
retention times of all compounds in the method and the overall run time, when compared with a 
manual method. The shortened run time of 6.2 minutes for MUSCLE compared with 8.2 minutes 
for the manual method did not compromise the separation of compounds with equal m/z. The 
sample with the optimal LC conditions was run number 117 in the sequence. During analysis of 
data an additional high throughput method was highlighted for accurately quantifying 25OHD3. 
This method separated 25OHD3 from 3-epi-25OHD3 and an isobar 7αC4 which has the same 
molecular weight. The total run time for this method was 3 minutes.  
 
Figure 1 displays overlaid chromatograms comparing the method developed with MUSCLE and 
the manually developed method, along with the chromatogram of the high throughput 25OHD3 
method. Details of the mobile phase methods optimised using MUSCLE and the manually 
developed method are displayed in Table 2 and an overlaid comparison of mobile phase 
gradients is shown in supplementary information Figure 1. The mobile phase associated with 
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the preferred MUSCLE method had a higher starting methanol concentration compared to the 
manual method, 72% compared with 64%. The mobile phase gradients were also different. The 
MUSCLE method was characterised by a convex gradient, whereas a linear gradient was used 
for the manual method. The convex gradient shortened the time for reaching maximum methanol 
required to elute the most polar vitamin D analogue, which also reduced retention times for each 
of the hydroxylated forms of vitamin D. Both the manual method and all samples run during the 
MUSCLE sequence could not completely separate the 24OHD2 and 25OHD2 compounds, 
although partial separation was achieved. Table 3 summarises the vitamin D retention times 
between methods. The mean shortening of analyte retention time using the MUSCLE method 
was 0.99 ±0.26 minutes. The mobile phase method which produced a high throughput method 
for 25OHD3 had a higher starting methanol mobile phase concentration (80%) and a concave 
gradient which rapidly increased the methanol at the beginning of the method.  
 
Cone voltage and collision energies of three principal metabolites in the method, 1α,25(OH)2D3, 
3-epi-25OHD3 and combined 24OHD2 and 25OHD2 were assessed for improvement in 
sensitivity based on the results obtained using MUSCLE, compared with manually optimised 
values. Cone voltage and desolvation temperatures for the entire method were also monitored 
and compared to manually optimised conditions. The collision energy and cone voltage effects 
on peak areas of 1α,25(OH)2D3, 3-epi-25OHD3 and combined 24OHD2 and 25OHD2 are 
displayed in Figure 2, along with the effects of the method cone voltage and desolvation 
temperatures on the peak area of all analytes in the method. These results confirmed that 
optimised values had already been obtained manually, as no significant improvement in peak 
area was observed. Although the peak area was increased at desolvation temperatures above 600 
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o
C, further analysis revealed no improvement in detection limits of analytes when the desolvation 
temperature was increased. The method therefore incorporated all of the mass spectrometry 
parameters that were optimised manually. 
 
A number of mass spectrometry conditions are being altered in tandem for each sample, as 
optimising one parameter each time would take an excessive length of time. This means 
individual compound results will be affected by the changes in desolvation temperatures along 
with their individual cone voltage and collision energy altered values. The accuracy of these 
mass spectrometry results could therefore be affected by the multiple parameters being optimised 
at the same time. A limitation observed with utilising this software was that the results listed by 
generation plateaued towards the higher generation values and the samples towards the end of 
the sequence, suggesting the full 200 samples was not required. 
 
The development of this method was performed on a Waters Xevo TQ-MS mass spectrometer. 
The limits of detections achieved with this system have restricted the quantitation of certain 
analytes within this method. Hence, under these parameters the observed limits of quantitation 
using MUSCLE do not achieve the required levels for assessing clinical reference concentrations 
ranges for all analytes assessed using this method. However incorporating these analyties into the 
method was still essential to ensure accurate quantitation by separating analytes of equal mass. 
The overall improved assay performance assessed for separation and quantitation does not apply 
to reducing quantitation limits to a point at which they can be routinely quantified for some of 
the analytes in this method. Specifically routine clinical measurements of 1α,25(OH)2D3 (15-60 
pg/mL)
13
 and to a lesser extend 24,25(OH)2D3, which clinically can be measured at low pg/mL 
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concentration ranges in patients with abnormalities.
14, 15
  It would also not be possible to measure 
circulating levels of 24OHD2 and 3-epi-25OHD2 which were incorporated into this method 
development to ensure 25OHD2 measurements are accurate. It was also important to 
demonstrate the separation of 23,25(OH)2D3 for accurate quantification of 1α,25(OH)2D3 and 
24,25(OH)2D3. Future studies are required to establish a MUSCLE method capable of routinely 
quantifying these analytes at levels below the quantitation limits achieved on this platform. 
These studies would focus on applying MUSCLE to develop this method on a later generation 
mass spectrometer platform that will improve limits of detection. In addition, the application of 
MUSCLE to develop a derivitisation method of these analytes on a later generation mass 
spectrometer would ensure the lower limits of quantitation are achieved.  
 
3.2 Method validation 
The accuracy and precision of both the MUSCLE and manual methods are displayed in Table 4. 
Both accuracy and precision were within acceptable guidelines outlined by the FDA. Post-
column infusion analysis of 25OHD3 was performed with method optimised manually, 
MUSCLE optimised method and 25OHD3 MUSCLE optimised method to assess any 
enhancement or suppression of the 25OHD3 signal owing to different retention times. The signal 
of 25OHD3 was compared in a vitamin D depleted serum, water sample and routine serum 
sample. The results from these infusion studies, displayed in supporting information Figure 2, 
showed no changes in signal enhancement or suppression, suggesting 25OHD3 analysis will not 
be affected by the altered mobile phase methods and retention times. 
 
Page 12 of 23Analytical Methods
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
A
na
ly
tic
al
M
et
ho
ds
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
20
 A
pr
il 
20
17
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f B
irm
in
gh
am
 o
n 
26
/0
4/
20
17
 0
9:
16
:1
8.
 
View Article Online
DOI: 10.1039/C7AY00550D
13 
 
Analysis of 10 routine human serum samples was performed using the manual method, 
MUSCLE optimised method and 25OHD3 MUSCLE optimised method to show standardisation 
and ensure no analyte bias between methods. Regression analysis between the methods is shown 
in Figure 3 and the deviation between methods is shown in supporting information Figure 3. 
Comparison of quantified 25OHD3 using the manual and MUSCLE methods gave a mean 
difference of 0.76% (95% CI 1.888 - -3.403) bias towards the MUSCLE method however this 
was not significant (t =0.937, P =0.768). There was a mean difference of 1.38% (95% CI 2.864 - 
-5.614) bias towards the 25OHD3 high throughput method in comparison to the manually 
developed, although this was not significant (t =0.935, P =0.995). All other metabolites 
quantified had varying degrees of mean bias (0.15-9.92%), however none of these differences 
were found to be significant and this bias was not always varied towards one particular method. 
 
4. Conclusion 
Data in this study confirm the efficacy of MUSCLE software in automating the development of a 
multiple vitamin D LC-MS/MS method. Incorporating this software into the development of this 
method shortened the chromatographic run time, whilst confirming the majority of the manually 
optimised mass spectrometry parameters. The MUSCLE software optimised the LC-MS/MS 
method for measuring 10 vitamin D metabolites, without affecting baseline separation of the 
metabolites. Baseline separation of compounds with equal m/z was also unaffected by the 
MUSCLE method. Applying this method improved the overall throughput by approximately 3.3 
hours per 100 samples, whilst reducing the method development time and labour. The optimum 
mass spectrometry results from the MUSCLE sequence matched with those that were previously 
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optimised manually, suggesting that the software is capable of achieving optimum mass 
spectrometry without the need for manual optimisation.  
 
In the current study a MUSCLE software strategy was used to further optimise a previously 
optimised method performed manually. A key advantage of MUSCLE has been demonstrated by 
the improvement of existing methods to enhance method throughput, and potentially improve 
sensitivity. In particular MUSCLE may help in the development of other vitamin D methods, 
particularly for alternative vitamin D pathways that are likely to have compounds with identical 
m/z .
5, 16
 MUSCLE has also been used previously to develop methods without prior knowledge of 
optimised method conditions.
4
 This would be beneficial for the development of LC-MS/MS 
methods in a number of fields such as clinical, pharmacology and metabolomics laboratories, in 
which high throughput methods are required while reducing the time and labour to develop these 
methods. 
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Tables 
 
Table 1 User defined minimum and maximum LC and MS optimisation parameters. 
 
LC mobile 
phase conditions 
Minimum 
value 
Maximum 
value 
Intermediate 
value 
Initial methanol mobile 
phase % 
60.0 80.0 2.0 
Final methanol mobile 
phase % 
90.0 100.0 1.0 
Ramp curve  3.0 9.0 1.0 
Ramp end (min) time 3.0 8.0 0.5 
MS conditions Minimum 
value 
Maximum 
value 
Intermediate 
value 
1α,25(OH)2D3 
cone voltage  
12 32 2 
1α,25(OH)2D3 
collision energy (V) 
24 44 2 
25OHD2+24OHD2 
cone voltage (V) 
16 36 2 
25OHD2+24OHD2 
collision energy (V) 
22 42 2 
3-epi-25OHD3 
cone voltage (V) 
16 36 2 
3-epi-25OHD3 
collision energy (V) 
22 42 2 
Cone voltage (V) 
 
14 
 
34 
 
2 
 
Desolvation temperature 
(
o
C) 
400 700 50 
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Table 2 Method inlet gradients. 
 
Manual method  MUSCLE method 
Time %Water %MeOH Gradient  Time %Water %MeOH Gradient 
Initial 36.0 64.0  
 
Initial 28.0 72.0  
5.25 5.5 94.5 6 - Linear 
 
3.00 3.0 97.0 7 – Convex 
5.60 36.0 64.0  6 
 
3.90 2.2 97.8 6- Linear 
5.60-
8.20 
36.0 64.0  
 
4.40 28.0 72.0 6 
    
 4.40-
6.20 
28.0 72.0  
25OHD3 MUSCLE method      
Time %Water %MeOH Gradient      
Initial 20.0 80.0  
 
    
2.20 7.0 93.0 3 - Concave 
 
    
2.50 20.0 80.0 6 
 
    
2.50-
3.00 
20.0 80.0  
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Table 3 List of vitamin D metabolites analysed and retention time changes between methods. 
 
Compound Abbrev. 
Manual 
Method RT 
(min) 
MUSCLE 
Method RT 
(min) 
25OHD3 
MUSCLE 
Method RT 
(min) 
25-HydroxyvitaminD3 25OHD3 3.65 2.76 1.51 
3-Epi-25-hydroxyvitaminD3 3-Epi25OHD3 4.28 3.28 1.82 
1α,25-DihydroxyvitaminD3 1α,25(OH)2D3 2.62 1.81 - 
23R,25-DihydroxyvitaminD3 23R,25(OH)2D3 3.21 2.36 - 
24R,25-DihydroxyvitaminD3 24R,25(OH)2D3 2.73 1.95 - 
25-HydroxyvitaminD2 25OHD2 3.83 2.93 - 
24-HydroxyvitaminD2 24OHD2 3.74 2.84 - 
3-Epi-25hydroxyvitaminD2 3-Epi-25OHD2 4.52 3.45 - 
1α,25- DihydroxyvitaminD2 1α,25(OH)2D2 3.16 2.32 - 
1α,24- DihydroxyvitaminD2 1α,24(OH)2D2 2.67 1.86 - 
Ergocalciferol Vitamin D2 4.90 3.40 - 
Cholecalciferol Vitamin D3 5.25 3.60 - 
7α-Hydroxy-4-cholesten-3-
one 
7αC4 4.01 3.08 1.70 
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Table 4 – Accuracy and precision for the manual and MUSCLE methods. 
 
    Manual method  MUSCLE method 
Compound 
 
Conc. 
(ng/mL) 
Level 
 Precision (%) RSD      Precision (%) RSD  
 Intra-day 
N=6 
Inter-day 
6+6+6 
Accuracy 
(%) 
 Inter-day 
6+6+6 
Inter-day 
6+6+6 
Accuracy 
(%) 
25OHD3 
1.00 
2.40 
Low 
Low 
  
5.4 
 
9.8 
 
99.5 
 7.7 
3.7 
9.6 
4.7 
98.9 
104.4 
12.0 Medium  6.8 7.4 95.3  3.5 4.4 106.3 
30.0 High  5.6 10.9 100.2  6.9 4.1 103.6 
  
  
 
  
    
 
3-Epi-25OHD3 
0.40 
1.20 
Low 
Low 
  
5.1 
 
5.4 
 
106.2 
 9.4 
4.6 
8.0 
5.9 
95.1 
109.0 
6.00 Medium  8.8 8.0 98.1  4.4 4.4 106.0 
15.0 High  8.0 7.4 93.1  4.3 5.6 103.8 
  
  
 
  
    
 
1α,25(OH)
2
D3 
0.30 
0.480 
Low 
Low 
  
2.5 
 
3.2 
 
97.2 
 8.8 
2.9 
10.4 
4.4 
97.9 
97.1 
2.40 Medium  7.1 3.9 93.5  2.2 3.0 98.8 
12.0 High  7.5 5.9 95.9  2.6 2.7 100.6 
  
  
 
  
    
 
24R,25(OH)
2
D3 
0.50 
1.20 
Low 
Low 
  
6.1 
 
8.1 
 
101.9 
 5.4 
4.4 
9.5 
4.5 
108.2 
98.2 
6.00 Medium  7.2 8.2 103.6  1.9 3.6 100.1 
15.0 High  6.0 8.4 103.8  6.4 7.1 94.9 
  
  
 
  
    
 
25OHD2 
0.40 
1.20 
Low 
Low 
  
8.3 
 
10.3 
 
97.1 
 4.3 
5.1 
5.0 
3.7 
89.0 
101.4 
6.00 Medium  7.8 7.9 93.1  6.0 3.5 98.4 
15.0 High  5.1 4.8 92.6  2.9 4.3 95.8 
           
 0.40 Low      10.0 9.7 101.3 
24OHD2 1.60 Medium      20.6 22.5 96.2 
 6.40 High      9.4 10.1 108.8 
           
 0.40 Low      7.9 7.1 104.6 
3-Epi-25OHD2 1.60 Medium      9.6 8.2 94.3 
 6.40 High      13.3 11.4 98.3 
           
 0.30 Low      9.2 10.9 94.7 
1α,25(OH)
2
D2 1.20 Medium      9.9 10.4 96.6 
 4.80 High      6.2 6.9 107.6 
           
 0.30 Low      13.7 13.8 90.9 
1α,24(OH)
2
D3 1.20 Medium      8.7 7.7 100.6 
 4.80 High      8.7 8.3 97.9 
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Figures 
 
Figure 1 Chromatograms showing a) overlaid analyses comparing the manually developed 
method, optimised MUSCLE method and 25OHD3 MUSCLE method of spiked analytes in 
methanol and water (50/50), b) individual compounds listed comparing manual and optimised 
MUSCLE methods of spiked analytes in charcoal stripped serum following an SLE extraction 
  
a) 
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b)  MUSCLE method    Manual method 
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Figure 2 MUSCLE mass spectrometry optimisation of cone voltage and collision energies on 
peak areas of individual compounds, along with the cone voltage and desolvation temperatures 
used for the entire method on peak areas of all analytes in the method. The manually optimised 
values were 1α,25(OH)2D3 cone voltage 24, collision energy 24; 3-epi-25OHD3 cone voltage 
26, collision energy 28; 25OHD2 cone voltage 22, collision energy 26; method cone voltage 24, 
desolvation temperature 550 
o
C 
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Figure 3 Regression analysis of the MUSCLE optimised methods compared with the manually 
developed method for a) 25OHD3, b) 3-epi-25OHD3, c) 25OHD2 and d) 24,25(OH)2D3 
concentrations analysed with routine serum samples (n=10). Two results for 25OHD2 were 
below the LLOQ have not been included. Regression lines and equations between the manual 
method and MUSCLE (dashed line) and 25OHD3 MUSCLE method (dotted line) are shown in 
a) and b). The regression line (solid line), 95% confidence intervals (dotted line) and regression 
equations are shown in c) and d) for comparison between the manual and MUSCLE method for 
25OHD2 and 24,25(OH)2D3 respectively 
 
a)                                                                       b) 
 
       c)                                                                         d) 
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